- Home
- SILO vs PHGE Comparison
SILO vs PHGE Comparison
Compare SILO & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- PHGE
- Stock Information
- Founded
- SILO 2010
- PHGE 2015
- Country
- SILO United States
- PHGE Israel
- Employees
- SILO N/A
- PHGE N/A
- Industry
- SILO Apparel
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- PHGE Health Care
- Exchange
- SILO Nasdaq
- PHGE Nasdaq
- Market Cap
- SILO 8.0M
- PHGE 7.8M
- IPO Year
- SILO N/A
- PHGE N/A
- Fundamental
- Price
- SILO $0.43
- PHGE $0.29
- Analyst Decision
- SILO
- PHGE Strong Buy
- Analyst Count
- SILO 0
- PHGE 1
- Target Price
- SILO N/A
- PHGE $15.00
- AVG Volume (30 Days)
- SILO 275.0K
- PHGE 1.8M
- Earning Date
- SILO 11-13-2025
- PHGE 11-12-2025
- Dividend Yield
- SILO N/A
- PHGE N/A
- EPS Growth
- SILO N/A
- PHGE N/A
- EPS
- SILO N/A
- PHGE N/A
- Revenue
- SILO $72,102.00
- PHGE N/A
- Revenue This Year
- SILO $1.86
- PHGE N/A
- Revenue Next Year
- SILO N/A
- PHGE N/A
- P/E Ratio
- SILO N/A
- PHGE N/A
- Revenue Growth
- SILO N/A
- PHGE N/A
- 52 Week Low
- SILO $0.36
- PHGE $0.25
- 52 Week High
- SILO $3.37
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- SILO 38.57
- PHGE 30.74
- Support Level
- SILO $0.39
- PHGE $0.25
- Resistance Level
- SILO $0.43
- PHGE $0.29
- Average True Range (ATR)
- SILO 0.04
- PHGE 0.04
- MACD
- SILO -0.00
- PHGE -0.01
- Stochastic Oscillator
- SILO 39.29
- PHGE 23.62
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).